Dopamine and Glutamate in Huntington's Disease: A Balancing Act
Open Access
- 6 May 2010
- journal article
- review article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 16 (3), 163-178
- https://doi.org/10.1111/j.1755-5949.2010.00134.x
Abstract
Huntington's disease (HD) is caused by a CAG repeat expansion in exon 1 of the HD gene resulting in a long polyglutamine tract in the N‐terminus of the protein huntingtin. Patients carrying the mutation display chorea in early stages followed by akinesia and sometimes dystonia in late stages. Other major symptoms include depression, anxiety, irritability or aggressive behavior, and apathy. Although many neuronal systems are affected, dysfunction and subsequent neurodegeneration in the basal ganglia and cortex are the most apparent pathologies. In HD, the primary hypothesis has been that there is an initial overactivity of glutamate neurotransmission that produces excitotoxicity followed by a series of complex changes that are different in the striatum and in the cortex. This review will focus on evidence for alterations in dopamine (DA)–glutamate interactions in HD, concentrating on the striatum and cortex. The most recent evidence points to decreases in DA and glutamate neurotransmission as the HD phenotype develops. However, there is some evidence for increased DA and glutamate functions that could be responsible for some of the early HD phenotype. Significant evidence indicates that glutamate and dopamine neurotransmission is affected in HD, compromising the fine balance in which DA modulates glutamate‐induced excitation in the basal ganglia and cortex. Restoring the balance between glutamate and dopamine could be helpful to treat HD symptoms.Keywords
This publication has 146 references indexed in Scilit:
- Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease miceNeuroscience, 2008
- Pallidal neuronal discharge in Huntington's disease: Support for selective loss of striatal cells originating the indirect pathwayExperimental Neurology, 2008
- Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s diseaseNeuroscience, 2007
- The corticostriatal pathway in Huntington's diseaseProgress in Neurobiology, 2007
- Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic MiceNeurobiology of Disease, 2001
- The Basal Ganglia and Adaptive Motor ControlScience, 1994
- Measurement of endogenous dopamine and norepinephrine release from superfused slices of rat prefrontal cortex in vitro: Modulation by D2 and alpha-2 presynaptic receptorsLife Sciences, 1991
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.Journal of Neurology, Neurosurgery & Psychiatry, 1984
- Regulation of [3H]5-hydroxytryptamine release from rat brain slicesJournal of Pharmacy and Pharmacology, 1974